Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

299 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Leveraging external data in the design and analysis of clinical trials in neuro-oncology.
Rahman R, Ventz S, McDunn J, Louv B, Reyes-Rivera I, Polley MC, Merchant F, Abrey LE, Allen JE, Aguilar LK, Aguilar-Cordova E, Arons D, Tanner K, Bagley S, Khasraw M, Cloughesy T, Wen PY, Alexander BM, Trippa L. Rahman R, et al. Among authors: bagley s. Lancet Oncol. 2021 Oct;22(10):e456-e465. doi: 10.1016/S1470-2045(21)00488-5. Lancet Oncol. 2021. PMID: 34592195 Free PMC article. Review.
Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients.
Lee EQ, Weller M, Sul J, Bagley SJ, Sahebjam S, van den Bent M, Ahluwalia M, Campian JL, Galanis E, Gilbert MR, Holdhoff M, Lesser GJ, Lieberman FS, Mehta MP, Penas-Prado M, Schreck KC, Strowd RE, Vogelbaum MA, Walbert T, Chang SM, Nabors LB, Grossman S, Reardon DA, Wen PY. Lee EQ, et al. Among authors: bagley sj. Neuro Oncol. 2020 May 15;22(5):601-612. doi: 10.1093/neuonc/noaa015. Neuro Oncol. 2020. PMID: 31974566 Free PMC article.
Systematic review of combinations of targeted or immunotherapy in advanced solid tumors.
Tan AC, Bagley SJ, Wen PY, Lim M, Platten M, Colman H, Ashley DM, Wick W, Chang SM, Galanis E, Mansouri A, Khagi S, Mehta MP, Heimberger AB, Puduvalli VK, Reardon DA, Sahebjam S, Simes J, Antonia SJ, Berry D, Khasraw M. Tan AC, et al. Among authors: bagley sj. J Immunother Cancer. 2021 Jul;9(7):e002459. doi: 10.1136/jitc-2021-002459. J Immunother Cancer. 2021. PMID: 34215688 Free PMC article. Review.
Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement.
Bagley SJ, Kothari S, Rahman R, Lee EQ, Dunn GP, Galanis E, Chang SM, Nabors LB, Ahluwalia MS, Stupp R, Mehta MP, Reardon DA, Grossman SA, Sulman EP, Sampson JH, Khagi S, Weller M, Cloughesy TF, Wen PY, Khasraw M. Bagley SJ, et al. Clin Cancer Res. 2022 Feb 15;28(4):594-602. doi: 10.1158/1078-0432.CCR-21-2750. Clin Cancer Res. 2022. PMID: 34561269 Free PMC article. Review.
Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma.
Singh K, Batich KA, Wen PY, Tan AC, Bagley SJ, Lim M, Platten M, Colman H, Ashley DM, Chang SM, Rahman R, Galanis E, Mansouri A, Puduvalli VK, Reardon DA, Sahebjam S, Sampson JH, Simes J, Berry DA, Zadeh G, Cloughesy TF, Mehta MP, Piantadosi S, Weller M, Heimberger AB, Khasraw M. Singh K, et al. Among authors: bagley sj. Clin Cancer Res. 2022 Feb 15;28(4):585-593. doi: 10.1158/1078-0432.CCR-21-2681. Clin Cancer Res. 2022. PMID: 34561270 Free PMC article. Review.
Correcting the drug development paradigm for glioblastoma requires serial tissue sampling.
Singh K, Hotchkiss KM, Parney IF, De Groot J, Sahebjam S, Sanai N, Platten M, Galanis E, Lim M, Wen PY, Minniti G, Colman H, Cloughesy TF, Mehta MP, Geurts M, Arrillaga-Romany I, Desjardins A, Tanner K, Short S, Arons D, Duke E, Wick W, Bagley SJ, Ashley DM, Kumthekar P, Verhaak R, Chalmers AJ, Patel AP, Watts C, Fecci PE, Batchelor TT, Weller M, Vogelbaum MA, Preusser M, Berger MS, Khasraw M. Singh K, et al. Among authors: bagley sj. Nat Med. 2023 Oct;29(10):2402-2405. doi: 10.1038/s41591-023-02464-8. Nat Med. 2023. PMID: 37488293 No abstract available.
A brave new framework for glioma drug development.
Hotchkiss KM, Karschnia P, Schreck KC, Geurts M, Cloughesy TF, Huse J, Duke ES, Lathia J, Ashley DM, Nduom EK, Long G, Singh K, Chalmers A, Ahluwalia MS, Heimberger A, Bagley S, Todo T, Verhaak R, Kelly PD, Hervey-Jumper S, de Groot J, Patel A, Fecci P, Parney I, Wykes V, Watts C, Burns TC, Sanai N, Preusser M, Tonn JC, Drummond KJ, Platten M, Das S, Tanner K, Vogelbaum MA, Weller M, Whittle JR, Berger MS, Khasraw M. Hotchkiss KM, et al. Among authors: bagley s. Lancet Oncol. 2024 Oct;25(10):e512-e519. doi: 10.1016/S1470-2045(24)00190-6. Lancet Oncol. 2024. PMID: 39362262 Review.
299 results